Literature DB >> 29784739

Management of Locoregional Rectal Cancer.

Christopher G Willett1.   

Abstract

The NCCN Guidelines for Rectal Cancer are now more closely aligned with those for colon cancer. A new MRI-based definition of the rectum has been included and the use of MRI in staging has been elevated in importance. There is a new emphasis on neoadjuvant therapy, especially the concurrent use of chemotherapy and radiotherapy. One of the biggest changes is more acceptance of an observational approach-"watch and wait, nonoperative management"-for select patients experiencing a complete clinical response with no evidence of residual disease after neoadjuvant therapy.
Copyright © 2018 by the National Comprehensive Cancer Network.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29784739     DOI: 10.6004/jnccn.2018.0037

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  4 in total

1.  Feasibility of Fitness Tracker Usage to Assess Activity Level and Toxicities in Patients With Colorectal Cancer.

Authors:  William H Ward; Caitlin R Meeker; Elizabeth Handorf; Maureen V Hill; Margret Einarson; R Katherine Alpaugh; Thomas L Holden; Igor Astsaturov; Crystal S Denlinger; Michael J Hall; Sanjay S Reddy; Elin R Sigurdson; Efrat Dotan; Matthew Zibelman; Joshua E Meyer; Jeffrey M Farma; Namrata Vijayvergia
Journal:  JCO Clin Cancer Inform       Date:  2021-01

Review 2.  Recent advances of neoadjuvant chemoradiotherapy in rectal cancer: Future treatment perspectives.

Authors:  Kimihiro Yamashita; Takeru Matsuda; Hiroshi Hasegawa; Junko Mukohyama; Akira Arimoto; Tomoko Tanaka; Masashi Yamamoto; Yoshiko Matsuda; Shingo Kanaji; Tetsu Nakamura; Yasuo Sumi; Satoshi Suzuki; Yoshihiro Kakeji
Journal:  Ann Gastroenterol Surg       Date:  2018-10-24

3.  Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial).

Authors:  Zhengyang Yang; Xiao Zhang; Jie Zhang; Jiale Gao; Zhigang Bai; Wei Deng; Guangyong Chen; Yongbo An; Yishan Liu; Qi Wei; Jiagang Han; Ang Li; Gang Liu; Yi Sun; Dalu Kong; Hongwei Yao; Zhongtao Zhang
Journal:  BMC Cancer       Date:  2022-04-27       Impact factor: 4.638

4.  Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.

Authors:  Ali Shamseddine; Youssef H Zeidan; Ziad El Husseini; Malek Kreidieh; Monita Al Darazi; Rim Turfa; Joseph Kattan; Ibrahim Khalifeh; Deborah Mukherji; Sally Temraz; Kholoud Alqasem; Rula Amarin; Tala Al Awabdeh; Samer Deeba; Faek Jamali; Issa Mohamad; Mousa Elkhaldi; Faiez Daoud; Mahmoud Al Masri; Ali Dabous; Ahmad Hushki; Omar Jaber; Maya Charafeddine; Fady Geara
Journal:  Radiat Oncol       Date:  2020-10-07       Impact factor: 3.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.